Literature DB >> 7283415

Standardized method for determining antimicrobial susceptibility of strains of Ureaplasma urealyticum and their response to tetracycline, erythromycin, and rosaramicin.

J A Robertson, J E Coppola, O R Heisler.   

Abstract

We describe a method for determining the minimal inhibitory concentrations (MICs) of antibiotics for Ureaplasma urealyticum which is compatible with current standard of susceptibility testing. A presumptive MIC is available after 24 h of incubation, and the definitive MIC is available at 48 h. The MICs for 9 serotype strains and 27 clinical isolates ranged from less than or equal to 0.5 to 256 microgram of tetracycline per ml, greater than or equal to 1 to 64 microgram of erythromycin per ml, and 0.031 to 4.0 microgram of rosaramicin per ml. Of an additional 555 isolates screened for their response to tetracycline, 2% required MICs of greater than 64 microgram/ml, which we believe is near the concentration at which in vivo resistance to this agent is expressed. After prolonged exposure to rosaramicin, the resistance of two of three serotype strains of U. urealyticum was increased 8- and 16-fold, but the MICs still did not exceed 1.0 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7283415      PMCID: PMC181631          DOI: 10.1128/AAC.20.1.53

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro activity of rosamicin, josamycin, erythromycin, and clindamycin against beta-lactamase-nagative and beta-lactamase-positive strains of Neisseria gonorrhoeae.

Authors:  J W Biddle; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

2.  Serotypic heterogeneity in isolates of human genital T-mycoplasmas.

Authors:  J S Lin; E H Kass
Journal:  Infect Immun       Date:  1973-03       Impact factor: 3.441

3.  Rosamicin, a macrolide with in vitro activity against Ureaplasma urealyticum.

Authors:  A C Hill; G Sutton
Journal:  J Antibiot (Tokyo)       Date:  1979-09       Impact factor: 2.649

4.  Modified metabolic inhibition test for serotyping strains of Ureaplasma urealyticum (T-strain Mycoplasma).

Authors:  J A Robertson; G W Stemke
Journal:  J Clin Microbiol       Date:  1979-06       Impact factor: 5.948

5.  T-strain Mycoplasma. Selective inhibition by erythromycin in vitro.

Authors:  M C Shepard; C D Lunceford; R L Baker
Journal:  Br J Vener Dis       Date:  1966-03

6.  In vitro activity of rosamicin against Neisseria and Haemophilus, including penicillinase-producing strains.

Authors:  C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

7.  In vitro susceptibility of Ureaplasma urealyticum to rosaramicin.

Authors:  T F Smith
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

8.  Susceptibility of genital mycoplasmas to antimicrobial agents.

Authors:  P Braun; J O Klein; E H Kass
Journal:  Appl Microbiol       Date:  1970-01

9.  Nongonococcal urethritis: a survey of clinical and laboratory features.

Authors:  T E Root; L D Edwards; P J Spengler
Journal:  Sex Transm Dis       Date:  1980 Apr-Jun       Impact factor: 2.830

10.  T mycoplasma in human reproductive failure.

Authors:  C D Graber; P Creticos; J Valicenti; H O Williamson
Journal:  Obstet Gynecol       Date:  1979-11       Impact factor: 7.661

View more
  10 in total

1.  In vitro susceptibility of tetracycline-resistant strains of Ureaplasma urealyticum to newer macrolides and quinolones, and a streptogramin.

Authors:  H Renaudin; C Bébéar; J A Robertson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

2.  Antibiotic sensitivity and mutation rates to antibiotic resistance in Mycoplasma mycoides ssp. mycoides.

Authors:  D H Lee; R J Miles; J R Inal
Journal:  Epidemiol Infect       Date:  1987-06       Impact factor: 2.451

3.  Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum.

Authors:  M C Roberts; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

4.  Comparison of methods for in vitro testing of susceptibility of porcine Mycoplasma species to antimicrobial agents.

Authors:  E A Ter Laak; A Pijpers; J H Noordergraaf; E C Schoevers; J H Verheijden
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

5.  Effects of manganese on the growth and morphology of Ureaplasma urealyticum.

Authors:  J A Robertson; M H Chen
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

6.  Successful treatment of preterm labour by eradication of Ureaplasma urealyticum with erythromycin.

Authors:  M Mazor; W Chaim; S Horowitz; J R Leiberman; M Glezerman
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

7.  Clinical and biological characteristics of Ureaplasma urealyticum induced polyarthritis in a patient with common variable hypogammaglobulinaemia.

Authors:  R R Lehmer; B S Andrews; J A Robertson; E J Stanbridge; L de la Maza; G J Friou
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

8.  Comparative in vitro activity of fleroxacin (RO 23-6240) against Ureaplasma urealyticum and Mycoplasma hominis.

Authors:  R Krausse; U Ullmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

9.  Mechanisms of macrolide resistance in Ureaplasma urealyticum: a study on collection and clinical strains.

Authors:  G Palù; S Valisena; M F Barile; G A Meloni
Journal:  Eur J Epidemiol       Date:  1989-06       Impact factor: 8.082

10.  In vitro susceptibility of Ureaplasma urealyticum and Mycoplasma hominis isolates in Argentina.

Authors:  J Smayevsky; S Relloso; M Pundik; A Lanza; G Weltman; C Bantar; H Bianchini
Journal:  Infect Dis Obstet Gynecol       Date:  1995
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.